Prostate Cancer Management with Multi-Modality Imaging

描述（由申请人提供）：除了传统的结构成像技术、计算机断层扫描（CT）、磁共振成像（MRI）和经直肠超声检查（TRUS）外，无创成像技术（包括放射性核素成像和磁共振波谱成像（MRSI））在前列腺癌治疗方面取得了实质性进展。然而，没有单一的成像技术已经证明了评估前列腺癌所需的功能的广度。此外，还没有建立一个连贯的多模态方法，使用这些已经可用的成像技术，这种疾病的临床管理。因此，我们建议开发一种方法，为同一患者提供一套全面的功能，代谢，生物分子和结构成像模式，以改善前列腺癌患者的管理。该项目的目标是开发一种方法，结合多种成像方式的信息，并开发一种方法，以改善目前的前列腺癌治疗前和治疗后的情况下管理。在这项研究中，我们将集中在双模态SPECT/CT成像使用铟-111放射性标记的单克隆抗体和MRI/MRSI技术在项目的初始阶段。 目标1：将开发一种方法，用商业SPECT/CT系统（Discovery VH豪克耶，GE Healthcare，沃基沙，WI）定量111 In标记的caporumab pendetide（ProstaScint（R），Cytogen Corporation，Princeton，NJ）在体模和患者中的活性。定量111 In-ProstaScint（R）摄取的方法将扩展到结合SPECT/CT和MRI/MRSI评估前列腺癌的方法。 目标2：我们将开发相关SPECT/CT和MRI/MRSI图像的方法，以评估具有转移性癌症高风险的患者，目的是辅助放射治疗计划。目标1和目标2所开展的111 In-ProstaScint（R）SPECT/CT和MRI/MRSI研究的定量测量和相关性可指导目标3所追求的放射治疗计划。 目标3：提出一种在放射治疗计划中实现相关图像显示的方法。 我们相信，从拟议的研究计划的成功完成的结果将不仅提高临床前列腺癌的管理，但也提供了宝贵的能力，技能和知识的候选人成为一个独立的生物医学研究人员在定量科学的强大背景。

DESCRIPTION (provided by applicant): Substantial advances in prostate cancer management have been made with noninvasive imaging techniques including radionuclide imaging and magnetic resonance spectroscopy imaging (MRSI) in addition to conventional structural imaging techniques, computed tomography (CT), magnetic resonance imaging (MRI), and transrectal ultrasonography (TRUS). However, no single imaging technique has demonstrated the breadth of functionality needed to assess prostate cancer. In addition, a coherent multimodality approach using these already available imaging techniques has not been established for the clinical management of this disease. We therefore propose to develop an approach to present a comprehensive set of functional, metabolic, biomolecular, and structural imaging modalities for the same patient to improve management of patients with prostate cancer. The goal of this project is to develop an approach that combines information from multiple imaging modalities and to develop a method to improve the current prostate cancer management in both pretherapy and posttherapy cases. In this study, we will focus on the dual-modality SPECT/CT imaging using an indium-111 radiolabeled monoclonal antibody and MRI/MRSI techniques during initial periods of the project. Goal 1: A method will be developed to quantify 111ln-labeled capromab pendetide (ProstaScint(R), Cytogen Corporation, Princeton, NJ) activity in phantoms and patients with a commercial SPECT/CT system (Discovery VH Hawkeye, GE Healthcare, Waukesha, Wl). The methods of quantifying 111ln-ProstaScint(R) uptake then will be extended to an approach that combines SPECT/CT and MRI/MRSI for assessment of prostate cancer. Goal 2: We will develop methods that correlate SPECT/CT and MRI/MRSI images to evaluate patients at a high risk of having metastasized cancer with a goal of assisting radiation treatment planning. The quantitative measurements and correlations from 111ln-ProstaScint( R)SPECT/CT and MRI/MRSI studies developed from Goal 1 and 2 then can guide radiation therapy planning which will be pursued under Goal 3. Goal 3: A method to implement the correlative image presentation in radiation treatment planning will be developed. We believe that outcomes from the successful completion of the proposed research program will not only enhance the clinical prostate cancer management but also provide valuable aptitude skills and knowledge for the candidate to become an independent biomedical researcher with strong background in quantitative sciences.